



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/336536/2023

European Medicines Agency decision P/0296/2023

of 11 August 2023

on the granting of a product specific waiver for semaglutide (Wegovy), (EMA-001441-PIP08-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/0296/2023

of 11 August 2023

on the granting of a product specific waiver for semaglutide (Wegovy), (EMA-001441-PIP08-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Novo Nordisk A/S on 20 March 2023 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 June 2023 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A waiver for Semaglutide(Wegovy), all pharmaceutical forms, all routes of administration, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Novo Nordisk A/S, Novo Alle 1, 2880 – Bagsværd, Denmark.

EMA/PDCO/146438/2023
Amsterdam, 23 June 2023

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-001441-PIP08-23

Scope of the application

Active substance(s):

Semaglutide

Invented name and authorisation status:

See Annex II

Condition(s):

Prevention of cardiovascular events in patients with atherosclerosis

Pharmaceutical form(s):

All pharmaceutical forms

Route(s) of administration:

All routes of administration

Name/corporate name of the PIP applicant:

Novo Nordisk A/S

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Novo Nordisk A/S submitted to the European Medicines Agency on 20 March 2023 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 24 April 2023.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Prevention of cardiovascular events in patients with atherosclerosis

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- all pharmaceutical forms, all routes of administration;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of Obesity

Authorised indication(s):

Adults

- Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of
 - ≥ 30 kg/m² (obesity), or
 - ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

Adolescents (≥ 12 years)

- Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with
 - obesity* and
 - body weight above 60 kg

Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.

**Obesity (BMI ≥ 95 th percentile) as defined on sex- and age-specific BMI growth charts (CDC gov)*

- Invented name(s): Wegovy
- Authorised pharmaceutical form(s): Solution for injection (injection)
- Authorised route(s) of administration: subcutaneous use
- Authorised via centralised procedure